A Phase III heart outcomes miss for ziltivekimab knocked 6.4% off Novo Nordisk’s shares and left the company more dependent than ever on its obesity franchise.
A Phase III heart outcomes miss for ziltivekimab knocked 6.4% off Novo Nordisk’s shares and left the company more dependent than ever on its obesity franchise.